NEW YORK, Aug. 1, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Coagulation Self-Testing: Devices, Markets, Players and
Prospects
http://www.reportlinker.com/p0581170/Coagulation-Self-Testing-Devices-Markets-Players-and-Prospects
.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
The ability of patients to self-monitor is deemed to be a
critical tool in reducing the pathological effects of
difficult-to-control disease factors. For the millions of patients
in the US and worldwide prescribed warfarin for oral
anticoagulation therapy (OAT), the ability to monitor coagulation
rates and adjust drug dosage to optimize therapeutic outcomes is a
critical element of patient care. The availability of self-testing
monitors provides patients with an opportunity to self-test and
avoid frequent caregiver visits. Compared to blood glucose
monitoring, OAT self-testing presents a higher level of complexity
and risk, placing a premium on patient education. A number of
companies are now providing services to patients wishing to
self-test, acting as a first-line patient resource and assisting
with device selection and patient training. Wirelessly-enabled
devices that allow patients to share readings with physicians
electronically provide an additional safety and compliance benefit.
While still a small percentage of all patients, as demographics and
awareness drive increases in the diagnosed incidence of underlying
conditions, patient self-testing for OAT will increasingly migrate
from caregiver facilities and into homes..
Highlights
• Analyzes marketed patient self-testing devices for
measuring and monitoring an
‘/>”/>
SOURCE